Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) - Equities research analysts at William Blair raised their FY2025 earnings per share estimates for shares of Telix Pharmaceuticals Limited American Depositary Shares in a research note issued on Tuesday, June 3rd. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of $0.83 for the year, up from their prior forecast of $0.82. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Telix Pharmaceuticals Limited American Depositary Shares' current full-year earnings is $0.24 per share.
Separately, Wedbush initiated coverage on Telix Pharmaceuticals Limited American Depositary Shares in a research report on Thursday. They set an "outperform" rating and a $22.00 target price on the stock.
Get Our Latest Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Price Performance
Shares of NASDAQ:TLX traded up $0.14 during trading on Friday, reaching $16.91. 15,674 shares of the company's stock traded hands, compared to its average volume of 25,974. Telix Pharmaceuticals Limited American Depositary Shares has a fifty-two week low of $13.61 and a fifty-two week high of $30.36. The company has a 50-day simple moving average of $16.76 and a 200-day simple moving average of $16.87.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Telix Pharmaceuticals Limited American Depositary Shares stock. Private Advisor Group LLC bought a new position in shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 10,140 shares of the company's stock, valued at approximately $170,000.
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Further Reading
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
